As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...

Common acne medications show surprising potential in lowering schizophrenia risk among vulnerable youth. Research suggests ...

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) just unveiled an announcement. Newron Pharmaceuticals has announced the US launch of its global Phase ...

Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares began Tuesday sharply higher. The company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...

Newron announces US initiation of its ENIGMA-TRS 2 Phase III global study of evenamide for patients with treatment-resistant ...

From recognising early signs to caregiving boundaries, experts and carers share practical strategies for supporting people ...

Boehringer Ingelheim plans to submit its app to treat under-addressed symptoms of schizophrenia for FDA clearance.

Panelists discuss how CT-155, a 16-week interactive digital application, met its primary end point in clinical trials by ...

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...